CALADRIUS BIOSCIENCES, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 5, 2015

Attached files

file filename
EX-10.2 - EXHIBIT 10.2 - CALADRIUS BIOSCIENCES, INC.exhibit102lsaamendment.htm
EX-10.3 - EXHIBIT 10.3 - CALADRIUS BIOSCIENCES, INC.exhibit103commonstockpurch.htm
EX-5.1 - EXHIBIT 5.1 - CALADRIUS BIOSCIENCES, INC.exhibit51paulhastingsopini.htm
EX-4.1 - EXHIBIT 4.1 - CALADRIUS BIOSCIENCES, INC.exhibit41registrationrights.htm
EX-31.2 - EXHIBIT 31.2 - CALADRIUS BIOSCIENCES, INC.clbs-ex312_20150930xq3.htm
EX-32.1 - EXHIBIT 32.1 - CALADRIUS BIOSCIENCES, INC.clbs-ex321_20150930xq3.htm
EX-31.1 - EXHIBIT 31.1 - CALADRIUS BIOSCIENCES, INC.clbs-ex311_20150930xq3.htm
EX-32.2 - EXHIBIT 32.2 - CALADRIUS BIOSCIENCES, INC.clbs-ex322_20150930xq3.htm
10-Q - 10-Q - CALADRIUS BIOSCIENCES, INC.clbs-10qx20150930.htm
v3.3.0.814
Label Element Value
Stock Issued During Period, Value, Warrant Exercises clbs_StockIssuedDuringPeriodValueWarrantExercises $ 1,720,725
Stock Issued During Period, Value, Acquisitions us-gaap_StockIssuedDuringPeriodValueAcquisitions 21,600,351
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation 8,941,452
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax 112
AOCI Attributable to Parent [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 112
Additional Paid-in Capital [Member]  
Stock Issued During Period, Value, Warrant Exercises clbs_StockIssuedDuringPeriodValueWarrantExercises 1,720,392
Stock Issued During Period, Value, New Issues us-gaap_StockIssuedDuringPeriodValueNewIssues 11,273,259
Stock Issued During Period, Value, Acquisitions us-gaap_StockIssuedDuringPeriodValueAcquisitions 21,595,021
Change in Ownership in Subsidiary clbs_ChangeinOwnershipinSubsidiary (86,617)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 299,594,525
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 343,308,264
Proceeds from Stock Options Exercised us-gaap_ProceedsFromStockOptionsExercised 270,959
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation 8,940,725
Common Stock [Member]  
Stock Issued During Period, Value, Warrant Exercises clbs_StockIssuedDuringPeriodValueWarrantExercises $ 333
Stock Issued During Period, Shares, New Issues us-gaap_StockIssuedDuringPeriodSharesNewIssues 1,850,081
Stock Issued During Period, Value, New Issues us-gaap_StockIssuedDuringPeriodValueNewIssues $ 1,850
Stock Issued During Period, Value, Acquisitions us-gaap_StockIssuedDuringPeriodValueAcquisitions $ 5,330
Stock Issued During Period, Shares, Warrants Exercised clbs_StockIssuedDuringPeriodSharesWarrantsExercised 333,250
Shares, Outstanding us-gaap_SharesOutstanding 27,196,537
Shares, Outstanding us-gaap_SharesOutstanding 35,485,523
Proceeds from option exercises, shares clbs_Proceedsfromoptionexercisesshares 48,987
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 27,197
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 35,486
Proceeds from Stock Options Exercised us-gaap_ProceedsFromStockOptionsExercised $ 49
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation 727,158
Stock Issued During Period, Shares, Acquisitions us-gaap_StockIssuedDuringPeriodSharesAcquisitions 5,329,510
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation $ 727
Noncontrolling Interest [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest (516,040)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest (944,300)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss (514,877)
Parent [Member]  
Stock Issued During Period, Value, Warrant Exercises clbs_StockIssuedDuringPeriodValueWarrantExercises 1,720,725
Stock Issued During Period, Value, New Issues us-gaap_StockIssuedDuringPeriodValueNewIssues 11,275,109
Stock Issued During Period, Value, Acquisitions us-gaap_StockIssuedDuringPeriodValueAcquisitions 21,600,351
Change in Ownership in Subsidiary clbs_ChangeinOwnershipinSubsidiary (86,617)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 62,542,475
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 63,003,272
Proceeds from Stock Options Exercised us-gaap_ProceedsFromStockOptionsExercised 271,008
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation 8,941,452
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss (43,261,343)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax 112
Retained Earnings [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest (236,373,605)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest (279,634,948)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss (43,261,343)
Treasury Stock [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest (705,742)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ (705,742)
Series B Preferred Stock [Member] | Preferred Stock [Member]  
Shares, Outstanding us-gaap_SharesOutstanding 10,000
Shares, Outstanding us-gaap_SharesOutstanding 10,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 100
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 100

CALADRIUS BIOSCIENCES, INC. Reports